Alvarez, Daniel F.
Wolbink, Gertjan
Cronenberger, Carol
Orazem, John
Kay, Jonathan
Funding for this research was provided by:
Pfizer
Article History
First Online: 29 September 2020
Declarations
:
: This review was sponsored by Pfizer.
: DFA is a full-time employee of and declares stock holdings or stock options from Pfizer. GW has nothing to disclose. CC and JO were employees of and held stock holdings or stock options from Pfizer at the time this manuscript was initiated. JK has received research support paid to his institution from AbbVie Inc., Genentech Inc., Gilead Sciences Inc., Pfizer, and UCB, Inc.; and consulting fees from AbbVie Inc., Amgen Inc., Alvotech Suisse AG, Boehringer Ingelheim GmbH, Celltrion Healthcare Co. Ltd, Janssen Biotech Inc., Merck Sharp & Dohme Corp., Mylan Inc., Novartis AG, Pfizer, Samsung Bioepis, Sandoz Inc., and UCB Inc.; and fees for participation in data monitoring boards from Bristol-Myers Squibb Company and Roche Laboratories Inc.
: DFA proposed the concept for the article. All authors drafted and/or critically revised the work for important intellectual content. DFA is the guarantor for the overall content.